Veillonellaceae

BacteriaBacillotaNegativicutesVeillonellalesVeillonellaceae
MCA-BAC-000049
TaxID: 31977 | Rank: family
Biology & Ecology
Biology
Gram Statusgram-negative
Oxygen Toleranceobligate anaerobe
Morphologynot applicable
Key Traits
  • short-chain fatty acid (SCFA) producer
Ecology
Primary Nichesgut, oral cavity
Reservoirhuman
Metabolites

No metabolite relationships documented for this taxon.

Clinical Profile
Pathobiont
yes no context dependent unknown
Clinical Rolesprotective commensal
Typical Specimenstool
Clinical Associations:
E1
E3 — Strong human clinical evidence E2 — Moderate human evidence E1 — Limited / preliminary
In a phase 1 FMT trial (n=10 anti-PD-1-refractory metastatic melanoma patients), Veillonellaceae relative abundance was higher in stool post-FMT plus nivolumab versus pretreatment (ANCOM); the responding FMT donor (Donor 1, whose recipients comprised all 3 clinical responders out of 5) was enriched for Veillonellaceae, and the paper explicitly characterizes the family as 'immunotherapy-favorable' based on prior anti-PD-1 cohort studies.
PMID: 33303685
D000069467 Fecal Microbiota Transplantation D000069196 Gastrointestinal Microbiome D000082082 Immune Checkpoint Inhibitors D008545 Melanoma H00038 Melanoma
Last reviewed: 2026-04-02
Evidence Timeline
Related Taxa Shared Niche = same body site   Shared Risk = same vulnerable population